{"result": {"id": "ae8c85a8-7a57-4f01-b3a4-bdb8b66b38e3", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CHINESE JOURNAL OF GENERAL PRACTICE<|>ORGANIZATION<|>The Chinese Journal of General Practice is a medical journal that published the article containing this drug information in September 2024\")\n##\n(\"entity\"<|>LDL-C<|>ORGANIZATION<|>Low-density lipoprotein cholesterol, a key biomarker targeted by PCSK9 inhibitors and other lipid-lowering therapies\")\n##\n(\"entity\"<|>TG<|>ORGANIZATION<|>Triglycerides, another lipid biomarker mentioned in relation to PCSK9 inhibitors' effects\")\n##\n(\"entity\"<|>STATINS<|>ORGANIZATION<|>Class of cholesterol-lowering drugs mentioned as being potentially combined with PCSK9 inhibitors\")\n##\n(\"entity\"<|>CHOLESTEROL ABSORPTION INHIBITORS<|>ORGANIZATION<|>Another class of drugs mentioned as being potentially combined with PCSK9 inhibitors\")\n##\n(\"entity\"<|>ARTERIOSCLEROTIC PLAQUES<|>ORGANIZATION<|>Plaques mentioned as being stabilized by PCSK9 inhibitors\")\n##\n(\"relationship\"<|>PCSK9 INHIBITORS<|>LDL-C<|>PCSK9 inhibitors work by lowering LDL-C levels<|>9)\n##\n(\"relationship\"<|>PCSK9 INHIBITORS<|>TG<|>PCSK9 inhibitors have weaker effects on TG compared to statins<|>5)\n##\n(\"relationship\"<|>PCSK9 INHIBITORS<|>STATINS<|>PCSK9 inhibitors can be combined with statins for enhanced cholesterol-lowering effects<|>8)\n##\n(\"relationship\"<|>PCSK9 INHIBITORS<|>CHOLESTEROL ABSORPTION INHIBITORS<|>PCSK9 inhibitors can be combined with cholesterol absorption inhibitors<|>7)\n##\n(\"relationship\"<|>PCSK9 INHIBITORS<|>ARTERIOSCLEROTIC PLAQUES<|>PCSK9 inhibitors help stabilize arteriosclerotic plaques<|>8)\n##\n(\"relationship\"<|>CHINESE JOURNAL OF GENERAL PRACTICE<|>PCSK9 INHIBITORS<|>The journal published research about PCSK9 inhibitors<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559224, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 528, "prompt_tokens": 3741, "total_tokens": 4269, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3648}, "prompt_cache_hit_tokens": 3648, "prompt_cache_miss_tokens": 93}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 1 次\nPCSK9 抑制剂\t依洛尤单抗\n　阿利西尤单抗 托莱西单抗\n英克司兰\t皮下注射，140 mg/次，每 2 周 1 次；或 420 mg/次，每 4 周 1 次 皮下注射，75 或 150 mg/次，每 2 周 1 次\n皮下注射，150 mg/次，每 2 周 1 次；或 450 mg/次，每 4 周 1 次；或 600 mg/次，每 6 周 1 次 皮下注射，284 mg/次，首次注射后 3 个月再次注射，之后每 6 个月1 次\n贝特类\t非诺贝特\n\n　吉非罗齐 苯扎贝特\n环丙贝特\t口服，片剂 0. 1 g/次，每日 3 次\n口服，胶囊 0.2 或 0.25 g/次，每日 1 次\n口服，0.3 或 0.6 g/次，每日 2 次\n口服，短效 0.2~0.4 g/次，每日 2 次 口服，缓释 0.4 g/次，每日 1 次\n口服，0. 1 g/次，每日 1 次\n处方级 ω?3 脂肪酸\tω?3 脂肪酸乙酯 90 软胶囊 多烯酸乙酯胶丸\t口服，2 g/次、每日 2 次；或 4 g/次、每日 1 次 口服，0.25 或 0.5 g/次，每日 3 次\n烟酸类\t烟酸缓释片 阿昔莫司\t口服，0.5~2 g/次，每日 1 次   口服，0.25 g/次，每日 2~3 次\n抗氧化类\n胆酸螯合剂\t普罗布考 考来烯胺 考来替泊 考来维仑\t口服，0.5 g/次，每日 2 次\n口服，5 g/次，每日 3 次\n口服，5 g/次，每日 3 次\n口服，1.875 g/次，每日 2 次\n注：PCSK9 前蛋白转化酶枯草溶菌素 9\n\n\n\n· 912   ·                                                       中华全科医师杂志 2024 年 9 月第 23 卷第 9 期    Chin J Gen Pract, September 2024, Vol. 23, No. 9\n\n\n解，从而增加细胞膜上 LDL?R 数量，促进 LDL?C 清  除［44］。此外，其还具有稳定动脉粥样硬化斑块、抗  凝和抗炎等作用［45?46］。然而，与他汀类药物相比， 其降低 TG 的作用较弱 。 因此，PCSK9 单克隆抗体  可作为单一疗法，或与他汀类药物或胆固醇吸收抑  制剂联合使用，以强化降低胆固醇疗效 。 目前临床  上常用的 PCSK9 单克隆抗体包括依洛尤单抗、阿利  西尤单抗和托莱西单抗等。\n　　英克司兰（inclisiran）是一种针对 PCSK9 的小 干扰 RNA（siRNA），可通过抑制 PCSK9 合成降低 LDL?C 水平［47］。英克司兰于 2023 年 8 月在中国获 批上市，用于成年人原发性高胆固醇血症和混合型 血脂异常的治疗 。主要适用于他汀类药物治疗后 LDL?C 未达目标值，以及不能耐\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>PCSK9 INHIBITORS<|>ORGANIZATION<|>PCSK9 inhibitors are a class of drugs that include evolocumab, alirocumab, and toleisumab, used to lower LDL-C levels by increasing LDL receptor numbers on cell membranes and promoting LDL-C clearance. They also have effects like stabilizing atherosclerotic plaques, anticoagulation, and anti-inflammation.\")\n##\n(\"entity\"<|>EVOLOCUMAB<|>ORGANIZATION<|>Evolocumab is a PCSK9 monoclonal antibody used to lower LDL-C levels, either as monotherapy or in combination with statins or cholesterol absorption inhibitors.\")\n##\n(\"entity\"<|>ALIROCUMAB<|>ORGANIZATION<|>Alirocumab is a PCSK9 monoclonal antibody used to lower LDL-C levels, either as monotherapy or in combination with statins or cholesterol absorption inhibitors.\")\n##\n(\"entity\"<|>TOLEISUMAB<|>ORGANIZATION<|>Toleisumab is a PCSK9 monoclonal antibody used to lower LDL-C levels, either as monotherapy or in combination with statins or cholesterol absorption inhibitors.\")\n##\n(\"entity\"<|>INCLISIRAN<|>ORGANIZATION<|>Inclisiran is a small interfering RNA (siRNA) targeting PCSK9, approved in China in August 2023 for treating primary hypercholesterolemia and mixed dyslipidemia in adults.\")\n##\n(\"entity\"<|>FIBRATES<|>ORGANIZATION<|>Fibrates are a class of drugs including fenofibrate, gemfibrozil, bezafibrate, and ciprofibrate, used to lower lipid levels.\")\n##\n(\"entity\"<|>FENOFIBRATE<|>ORGANIZATION<|>Fenofibrate is a fibrate drug used to lower lipid levels, available in oral tablet form.\")\n##\n(\"entity\"<|>GEMFIBROZIL<|>ORGANIZATION<|>Gemfibrozil is a fibrate drug used to lower lipid levels, available in oral capsule form.\")\n##\n(\"entity\"<|>BEZAFIBRATE<|>ORGANIZATION<|>Bezafibrate is a fibrate drug used to lower lipid levels, available in oral form.\")\n##\n(\"entity\"<|>CIPROFIBRATE<|>ORGANIZATION<|>Ciprofibrate is a fibrate drug used to lower lipid levels, available in oral form.\")\n##\n(\"entity\"<|>OMEGA-3 FATTY ACIDS<|>ORGANIZATION<|>Omega-3 fatty acids, including ethyl esters and polyene ethyl ester soft capsules, are used to manage lipid levels.\")\n##\n(\"entity\"<|>NIACIN<|>ORGANIZATION<|>Niacin, including extended-release tablets and acipimox, is used to manage lipid levels.\")\n##\n(\"entity\"<|>ANTIOXIDANTS<|>ORGANIZATION<|>Antioxidants like probucol are used to manage lipid levels.\")\n##\n(\"entity\"<|>BILE ACID SEQUESTRANTS<|>ORGANIZATION<|>Bile acid sequestrants like cholestyramine, colestipol, and colesevelam are used to manage lipid levels.\")\n##\n(\"relationship\"<|>EVOLOCUMAB<|>PCSK9 INHIBITORS<|>Evolocumab is a type of PCSK9 inhibitor<|>9)\n##\n(\"relationship\"<|>ALIROCUMAB<|>PCSK9 INHIBITORS<|>Alirocumab is a type of PCSK9 inhibitor<|>9)\n##\n(\"relationship\"<|>TOLEISUMAB<|>PCSK9 INHIBITORS<|>Toleisumab is a type of PCSK9 inhibitor<|>9)\n##\n(\"relationship\"<|>INCLISIRAN<|>PCSK9 INHIBITORS<|>Inclisiran is a type of PCSK9 inhibitor<|>9)\n##\n(\"relationship\"<|>FENOFIBRATE<|>FIBRATES<|>Fenofibrate is a type of fibrate<|>9)\n##\n(\"relationship\"<|>GEMFIBROZIL<|>FIBRATES<|>Gemfibrozil is a type of fibrate<|>9)\n##\n(\"relationship\"<|>BEZAFIBRATE<|>FIBRATES<|>Bezafibrate is a type of fibrate<|>9)\n##\n(\"relationship\"<|>CIPROFIBRATE<|>FIBRATES<|>Ciprofibrate is a type of fibrate<|>9)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_646b6077d0c4b9f96aa2c000c4ca9ff22a4fc99701744e5577e4481c7e341c23_v2"}